RankingsPricing
  1. US-listed companies
  2. Akebia Therapeutics, Inc.
  3. Financials
  4. Cash and cash equivalents

Akebia Therapeutics, Inc.AKBA

Market cap
$438.6M
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 202454+20.12%
Dec 31, 202345-52.15%
Dec 31, 202293-38.64%
Dec 31, 2021152-34.31%
Dec 31, 2020231+54.29%
Dec 31, 2019150+39.87%
Dec 31, 2018107+52.66%
Dec 31, 201770-62.55%
Dec 31, 2016187+276.34%
Dec 31, 201550+51.85%
Dec 31, 201433

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)